What is the Place of Fluoroquinolones in the Treatment of Community-Acquired Respiratory Tract Infections?

ISSN： 0012-6667

Source： Drugs, Vol.57, Iss.6, 1999-06, pp. : 851-853

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Evaluation and cost assessment of fluoroquinolones in community-acquired respiratory infections

By Sahloff Eric G Close Sandy J Martin Steven J

Expert Opinion on Pharmacotherapy, Vol. 3, Iss. 9, 2002-09 ,pp. : 1251-1266

Informa Healthcare

Access to resources Recommend Favorite

Pharmacokinetics and Pharmacodynamics of Newer Oral Cephalosporins: Implications for Treatment of Community-Acquired Lower Respiratory Tract Infections

By Cazzola M. Matera M.G. Donner C.F.

Clinical Drug Investigation, Vol. 16, Iss. 4, 1998-10 ,pp. : 335-346

Adis International

Access to resources Recommend Favorite

Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin

By Nicolau David P

Expert Opinion on Pharmacotherapy, Vol. 5, Iss. 2, 2004-02 ,pp. : 229-235

Informa Healthcare

Access to resources Recommend Favorite

Clarithromycin extended-release in community-acquired respiratory tract infections

By Williams Kathy N Bishai William R

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 16, 2005-12 ,pp. : 2867-2876

Informa Healthcare

Access to resources Recommend Favorite

Use of cethromycin, a new ketolide, for treatment of community-acquired respiratory infections

By Hammerschlag Margaret R Sharma Roopali

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 3, 2008-03 ,pp. : 387-400

Informa Healthcare

Access to resources Recommend Favorite